Sodium restrictions in heart failure

Alex Haga — Tue, 28 Jan 2025 00:24:48 +0000

Date Added:

January 27, 2025

Journal/Publication:

Canadian Family Physician

Publication Date:

January 1, 2025

Issue:

Volume:

Pages:

URL:

Sodium restrictions in heart failure

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.46747/cfp.710141

Keywords

Sodium

dietary

chronic heart failure

PMID (1):

39843182

MeSH

Sodium

Dietary

heart failure

Dietary sodium intake of less than 2 gm per day is no better than 2 - 3 gm per day for reducing hospitalizations or death. James W. Mold, MD, MPH

Free full text

View

Clinical question
Does sodium restriction improve outcomes in patients with chronic heart failure (CHF)?

Bottom line
In patients with CHF, restricting dietary sodium to less than 2 g/day does not reduce death or hospitalization compared with 2 to 3 g/day.

Author/s:

Ricky D Turgeon, James P McCormack, Jen Potter

Management of Heart Failure

Aubrey Delammermore — Sat, 24 Sep 2022 05:00:00 +0000

Date Added:

September 24, 2022

Journal/Publication:

JAMA Clinical Guidelines Synopsis

Publisher:

American Medical Association

Publication Date:

September 15, 2022

Pages:

E1-E2

URL:

Management of Heart Failure

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1001/jama.2022.16667

Keywords

Stroke Volume

American Heart Association

Cardiology

heart failure

Sodium

PMID (1):

36107415

MeSH

Mineralocorticoid Receptor Antagonists

Angiotensin Receptor Antagonists

Sodium-Glucose Transporter 2 Inhibitors

Angiotensin-Converting Enzyme Inhibitors

Angioedema

Updated guidelines for management of congestive heart failure rom the American College of Cardiology and the American Heart Association. James W. Mold, MD, MPH

Free full text

View

GUIDELINE TITLE 2022 American College of Cardiology
(ACC)/American Heart Association AHA)/Heart Failure
Society of America (HFSA) Guidelines for the Management
of Heart Failure
RELEASE DATE April 1, 2022
PRIOR VERSIONS 2017 ACC/AHA/HFSA Focused Update
of the 2013 ACCF/AHA Guideline for the Management of
Heart Failure and 2013 ACCF/AHA Guideline for the
Management of Heart Failure
DEVELOPER AND FUNDING SOURCE ACC/AHA Joint
Committee on Clinical Practice Guidelines
TARGET POPULATION Adult patients with a diagnosis of
or at risk for heart failure (HF)
MAJOR RECOMMENDATIONS
• Classifications for HF are separated into 4 categories based
on ejection fraction (EF) and disease history: HF with
reduced EF (EF 40%), HF with mildly reduced EF
(EF 41%-49%), HF with preserved EF (EF 50%), and HF
with improved EF (EF previously 40% with improvement
to >40%).
• In patients with chronic HF with reduced EF, angiotensin
receptor–neprilysin inhibitors (ARNIs) are preferred over
angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II receptor blockers (ARBs). If ARNI use is not
feasible, ACEIs are preferred over ARBs, unless there is
significant cough or angioedema (class 1, level of
evidence [LOE] A).
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors should
be included across all HF categories (symptomatic HF with
reduced EF [class 1, LOE A]; HF with mildly reduced EF and
HF with preserved EF [class 2a, LOE B-R]).
• Patients with HF with improved EF should continue to
receive medical therapy originally indicated for HF with
reduced EF (class 1, LOE B-R).
• Evidence-based treatment of HF with preserved EF
includes blood pressure control (class 1, LOE C-LD),
SGLT2 inhibitors (class 2a, LOE B-R), mineralocorticoid
antagonists, ARBs, and ARNIs (class 2b, LOE B-R).

Author/s:

Belkin, M. N., Cifu, A. S., Pinney, S.